In­cyte nabs pri­or­i­ty re­view for bile duct can­cer drug; Temasek shows in­ter­est in an­oth­er Wood­ford dar­ling — re­port

→ In­cyte’s de­ci­sion to stop co-fund­ing baric­i­tinib in fa­vor of oth­er pipeline op­por­tu­ni­ties is pay­ing off, as the FDA grants pri­or­i­ty re­view to pemi­ga­tinib in a type of pre­vi­ous­ly treat­ed, lo­cal­ly ad­vanced or metasta­t­ic cholan­gio­car­ci­no­ma. Pa­tients cur­rent­ly have “lim­it­ed treat­ment op­tions be­yond first-line chemother­a­py and of­ten face a poor prog­no­sis,” said Pe­ter Lang­muir, group vice pres­i­dent for tar­get­ed ther­a­peu­tics. The drug in­hibits fi­brob­last growth fac­tor re­cep­tor, or FGFR, and has been shown to in­duce an over­all re­sponse rate of 36% with a me­di­an du­ra­tion of re­sponse of 7.5 months among pa­tients with FGFR2 fu­sions or re­arrange­ments. The PDU­FA date is set for May 30, 2020.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER